http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020287328-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0679 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12M25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0697 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate | 2020-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a88fb771c2db26068c5de04096a0ef95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_422f7eb3f220fff4019fd956e0ab5c62 |
| publicationDate | 2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2020287328-A1 |
| titleOfInvention | Uses of patient-derived intestinal organoids for celiac disease diagnosis, screening and treatment |
| abstract | Air-liquid interface organoid cultures are initiated from human small intestine biopsy tissue comprising both the syngeneic intestinal epithelium and native intestinal immune cells, without reconstitution, which may be obtained from an individual pre-disposed or suffering from celiac disease. The organoid cultures exhibit T cell activation in response to in vitro gluten challenge and provide tools for a novel diagnostic method for celiac disease. Diagnosis may comprise the addition of immunogenic gluten-derived peptides into the organoid cultures, and assessing hallmarks of active celiac disease, including without limitation: 1) gliadin-presentation, resulting T-cell responses, such as 2) expansion and 3) activation, 4) epithelial-cell death and consequent 5) increased proliferative epithelial cell responses to gliadin. Celiac patients, either in GRD or GFD, test positive for these tests. In other embodiments the organoids are used to test responses to candidate therapeutic agents, assessing reduction of gliadin-dependent (1) T cell activation or expansion, or (2) organoid epithelial cell death. |
| priorityDate | 2019-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 351.